Lucia De Franceschi

List of Publications by Year
in descending order

203	7,147	76326	71685
papers	citations	40 h-index	76 g-index

207	207	207	8863
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Italian patients with hemoglobinopathies exhibit a 5â€fold increase in ageâ€standardized lethality due to SARSâ€CoVâ€2 infection. American Journal of Hematology, 2022, 97, .	4.1	7
2	Transfusional Approach in Multi-Ethnic Sickle Cell Patients: Real-World Practice Data From a Multicenter Survey in Italy. Frontiers in Medicine, 2022, 9, 832154.	2.6	2
3	Thalassaemia is paradoxically associated with a reduced risk of inâ€hospital complications and mortality in COVIDâ€19: Data from an international registry. Journal of Cellular and Molecular Medicine, 2022, 26, 2520-2528.	3.6	6
4	Adaptative Up-Regulation of PRX2 and PRX5 Expression Characterizes Brain from a Mouse Model of Chorea-Acanthocytosis. Antioxidants, 2022, 11, 76.	5.1	5
5	Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease. Haematologica, 2022, 107, 2650-2660.	3.5	8
6	Redox Balance in Î²-Thalassemia and Sickle Cell Disease: A Love and Hate Relationship. Antioxidants, 2022, 11, 967.	5.1	5
7	Pharmacological Induction of Fetal Hemoglobin in Î²-Thalassemia and Sickle Cell Disease: An Updated Perspective. Pharmaceuticals, 2022, 15, 753.	3.8	14
8	Tyrosine Phosphorylation Modulates Peroxiredoxin-2 Activity in Normal and Diseased Red Cells. Antioxidants, 2021, 10, 206.	5.1	4
9	Novel inhibitors of human glucose-6-phosphate dehydrogenase (HsG6PD) affect the activity and stability of the protein. Biochimica Et Biophysica Acta - General Subjects, 2021, 1865, 129828.	2.4	6
10	Selecting Î²-thalassemia Patients for Gene Therapy: A Decision-making Algorithm. HemaSphere, 2021, 5, e555.	2.7	4
11	The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a Î²-thalassemia mouse model. Journal of Clinical Investigation, 2021, 131, .	8.2	39
12	Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis. Acta Neuropathologica Communications, 2021, 9, 81.	5.2	19
13	Dietary Ï‰-3 Fatty Acid Supplementation Improves Murine Sickle Cell Bone Disease and Reprograms Adipogenesis. Antioxidants, 2021, 10, 799.	5.1	3
14	Targeting Lyn Kinase in Chorea-Acanthocytosis: A Translational Treatment Approach in a Rare Disease. Journal of Personalized Medicine, 2021, 11, 392.	2.5	8
15	The EHA Research Roadmap: Anemias. HemaSphere, 2021, 5, e607.	2.7	7
16	Recommendations for diagnosis and treatment of methemoglobinemia. American Journal of Hematology, 2021, 96, 1666-1678.	4.1	56
17	Children and their being "carnivorous": is visceral adiposity protection or promotion?. Minerva Pediatrics, 2021, , .	0.4	0
18	Atypical hemolytic uremic syndrome: Unique clinical presentation linked to rare CFHR5 mutation. EJHaem, 2021, 2, 838-841.	1.0	1

#	Article	IF	Citations
19	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 742	9.1	1,430
20	The Increased Burden of Sickle Cell Disease in Italy: Findings from the Greatalys (Generating Real) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.4	1
21	Trial in Progress: The Randomized, Double-Blind, Placebo-Controlled Phase Ib CROSSWALK-a Trial Evaluating the Safety of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOEs) in Patients with Sickle Cell Disease (SCD). Blood, 2021, 138, 3108-3108.	1.4	3
22	The EHA Research Roadmap: Normal Hematopoiesis. HemaSphere, 2021, 5, e669.	2.7	1
23	Nrf2 Plays a Key Role in Iron-Overload Cardiomyopathy. Blood, 2021, 138, 3068-3068.	1.4	0
24	Summary of Joint European Hematology Association (EHA) and EuroBloodNet Recommendations on Diagnosis and Treatment of Methemoglobinemia. HemaSphere, 2021, 5, e660.	2.7	1
25	Mitapivat Improves Transfusion Burden and Reduces Iron Overload in Thalassemic Mice. Blood, 2021, 138, 2016-2016.	1.4	1
26	Acute haemolysis by cold antibody during SARS-CoV-2 infection in a patient with Evans syndrome: a case report and literature review. Blood Transfusion, 2021, , .	0.4	2
27	Emerging drugs in randomized controlled trials for sickle cell disease: are we on the brink of a new era in research and treatment?. Expert Opinion on Investigational Drugs, 2020, 29, 23-31.	4.1	15
28	Effects of hypoxiaâ€“reoxygenation stimuli on renal redox status and nuclear factor erythroid 2â€•related factor 2 pathway in sickle cell SAD mice. Experimental Physiology, 2020, 105, 357-369.	2.0	0
29	Genetic disruption of KCC cotransporters in a mouse model of thalassemia intermedia. Blood Cells, Molecules, and Diseases, 2020, 81, 102389.	1.4	5
30	Fyn specifically Regulates the activity of red cell glucose-6-phosphate-dehydrogenase. Redox Biology, 2020, 36, 101639.	9.0	14
31	A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 19. Thrombosis Research, 2020, 193, 170-172.	1.7	57
32	Recommendations for Pregnancy in Rare Inherited Anemias. HemaSphere, 2020, 4, e446.	2.7	8
33	Glucose-6-phosphate dehydrogenase deficiency associated hemolysis in COVID-19 patients treated with hydroxychloroquine/chloroquine: New case reports coming out. European Journal of Internal Medicine, 2020, 80, 103.	2.2	4
34	Acute hemolysis by hydroxycloroquine was observed in G6PD-deficient patient with severe COVD-19 related lung injury. European Journal of Internal Medicine, 2020, 77, 136-137.	2.2	19
35	Care of patients with hemoglobin disorders during the <scp>COVID</scp>â€19 pandemic: An overview of recommendations. American Journal of Hematology, 2020, 95, E208-E210.	4.1	24
36	The psychophysical impact that COVIDâ€19 has on children must not be underestimated. Acta Paediatrica, International Journal of Paediatrics, 2020, 109, 1679-1680.	1.5	10

#	Article	IF	Citations
37	Development of Algorithm for Clinical Management of Sickle Cell Bone Disease: Evidence for a Role of Vertebral Fractures in Patient Follow-up. Journal of Clinical Medicine, 2020, 9, 1601.	2.4	12
38	Oxidation Impacts the Intracellular Signaling Machinery in Hematological Disorders. Antioxidants, 2020, 9, 353.	5.1	6
39	<scp>SARSâ€CoV</scp>â€2 infection in beta thalassemia: Preliminary data from the Italian experience. American Journal of Hematology, 2020, 95, E198-E199.	4.1	56
40	Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversed by blood transfusion. Blood, 2020, 135, 2071-2084.	1.4	44
41	COVID 19 and Hemoglobinopathies: Update of the Italian Experience. Blood, 2020, 136, 17-18.	1.4	0
42	The Pyruvate Kinase Activator Mitapivat Ameliorates Anemia and Prevents Iron Overload in a Mouse Model of Hereditary Spherocytosis. Blood, 2020, 136, 29-29.	1.4	3
43	Complement activation in the plasma and placentas of women with different subsets of antiphospholipid syndrome. American Journal of Reproductive Immunology, 2019, 82, e13185.	1.2	14
44	Postural counseling represents a novel option in pain management of fibromyalgia patients. Journal of Pain Research, 2019, Volume 12, 327-337.	2.0	3
45	Current challenges in the management of patients with sickle cell disease â€“ A report of the Italian experience. Orphanet Journal of Rare Diseases, 2019, 14, 120.	2.7	24
46	PIEZO1 Hypomorphic Variants in Congenital Lymphatic Dysplasia Cause Shape and Hydration Alterations of Red Blood Cells. Frontiers in Physiology, 2019, 10, 258.	2.8	26
47	Access to emergency departments for acute events and identification of sickle cell disease in refugees. Blood, 2019, 133, 2100-2103.	1.4	24
48	Oxidation and erythropoiesis. Current Opinion in Hematology, 2019, 26, 145-151.	2.5	14
49	EHA Research Roadmap on Hemoglobinopathies and Thalassemia: An Update. HemaSphere, 2019, 3, e208.	2.7	13
50	Resolution of sickle cell diseaseâ€“associated inflammation and tissue damage with 17R-resolvin D1. Blood, 2019, 133, 252-265.	1.4	50
51	NEW THERAPEUTIC OPTIONS FOR THE TREATMENT OF SICKLE CELL DISEASE. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019002.	1.3	29
52	Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule. Haematologica, 2019, 104, 919-928.	3.5	34
53	Fyn kinase is a novel modulator of erythropoietin signaling and stress erythropoiesis. American Journal of Hematology, 2019, 94, 10-20.	4.1	28
54	Bitopertin, a selective oral GLYT1 inhibitor, improves anemia in a mouse model of Î²-thalassemia. JCI Insight, 2019, 4, .	5.0	19

#	Article	IF	Citations
55	Selecting ÃŸ-Thalassemia Patients for Gene Therapy: A Decision-Making Algorithm. Blood, 2019, 134, 972-972.	1.4	2
56	Magnesium for treating sickle cell disease. The Cochrane Library, 2019, 2019, CD011358.	2.8	4
57	The Novel Role That Nrf2 Plays in Erythropoiesis during Aging. Blood, 2019, 134, 3502-3502.	1.4	0
58	Fyn Specifically Regulates the Activity of Red Cell Glucose-6-Phosphate-Dehydrogenase. Blood, 2019, 134, 3527-3527.	1.4	0
59	The Vasculopathy in the Bone Marrow Microenvironment of Humanized Sickle Cell Mice Is Reversible By Blood Transfusion. Blood, 2019, 134, 2256-2256.	1.4	0
60	Red blood cell alloimmunisation in transfusion-dependent thalassaemia: a systematic review. Blood Transfusion, 2019, 17, 4-15.	0.4	28
61	Microcytosis is important in screening of iron deficiency anemia. European Journal of Internal Medicine, 2018, 48, e39.	2.2	0
62	PIEZO1-R1864H rare variant accounts for a genetic phenotype-modifier role in dehydrated hereditary stomatocytosis. Haematologica, 2018, 103, e94-e97.	3.5	18
63	Lack of correlation between heart, liver and pancreas <scp>MRI</scp>â€<scp>R</scp>2*: Results from longâ€term followâ€up in a cohort of adult Î²â€thalassemia major patients. American Journal of Hematology, 2018, 93, E79-E82.	4.1	14
64	Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent. Blood Cells, Molecules, and Diseases, 2018, 69, 82-89.	1.4	34
65	Peroxiredoxin-2: A Novel Regulator of Iron Homeostasis in Ineffective Erythropoiesis. Antioxidants and Redox Signaling, 2018, 28, 1-14.	5.4	33
66	Persistent abdominal pain related to portal vein thrombosis in young adult with sickle cell disease. American Journal of Hematology, 2018, 93, 1562-1565.	4.1	1
67	Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusionâ€dependent thalassemia patients. American Journal of Hematology, 2018, 93, E338-E340.	4.1	6
68	Improvement of maternal and fetal outcomes in women with sickle cell disease treated with early prophylactic erythrocytapheresis. Transfusion, 2018, 58, 2192-2201.	1.6	22
69	Imatinib Protects Against Hypoxia/Reoxygenation Induced Lung and Kidney Injury in a Humanized Mouse Model for SCD. Blood, 2018, 132, 725-725.	1.4	1
70	Transfusion Therapy in a Multi-Ethnic Sickle Cell Population Real-World Practice. a Preliminary Data Analysis of Multicentre Survey. Blood, 2018, 132, 2389-2389.	1.4	3
71	Dietary Omega-3 Fatty Acid Supplementation Improves Sickle Cell Bone Disease By Affecting Osteoblastogenesis and Adipogenesis. Blood, 2018, 132, 2356-2356.	1.4	0
72	Hemolytic anemia repressed hepcidin level without hepatocyte iron overload: lesson from GÃ¼nther disease model. Haematologica, 2017, 102, 260-270.	3.5	13

#	Article	IF	Citations
73	Magnesium for treating sickle cell disease. The Cochrane Library, 2017, 4, CD011358.	2.8	10
74	Hemopexin counteracts systolic dysfunction induced by heme-driven oxidative stress. Free Radical Biology and Medicine, 2017, 108, 452-464.	2.9	38
75	Data demonstrating the anti-oxidant role of hemopexin in the heart. Data in Brief, 2017, 13, 69-76.	1.0	13
76	Clinical management of iron deficiency anemia in adults: Systemic review on advances in diagnosis and treatment. European Journal of Internal Medicine, 2017, 42, 16-23.	2.2	76
77	Recommendations regarding splenectomy in hereditary hemolytic anemias. Haematologica, 2017, 102, 1304-1313.	3.5	138
78	Treatment of hepatitis C virus infection with directâ€acting antiviral drugs is safe and effective in patients with hemoglobinopathies. American Journal of Hematology, 2017, 92, 1349-1355.	4.1	42
79	Data demonstrating the role of peroxiredoxin 2 as important anti-oxidant system in lung homeostasis. Data in Brief, 2017, 15, 376-381.	1.0	0
80	Peroxiredoxin-2 plays a pivotal role as multimodal cytoprotector in the early phase of pulmonary hypertension. Free Radical Biology and Medicine, 2017, 112, 376-386.	2.9	28
81	Fyn Kinase Is Involved in EPO Receptor Signaling and Is Required to Harmonize the Response to Oxidation. Blood, 2017, 130, 9-9.	1.4	1
82	Eighth International Chorea-Acanthocytosis Symposium: Summary of Workshop Discussion and Action Points. Tremor and Other Hyperkinetic Movements, 2017, 7, 428.	2.0	2
83	Band 3 Erythrocyte Membrane Protein Acts as Redox Stress Sensor Leading to Its Phosphorylation by p⁷²Syk. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-11.	4.0	60
84	Red Blood Cell Homeostasis: Pharmacological Interventions to Explore Biochemical, Morphological and Mechanical Properties. Frontiers in Molecular Biosciences, 2016, 3, 10.	3.5	20
85	Late Breaking Science502Hemopexin counteracts systolic dysfunction induced by heme overload503Inhibition of NF-kappa B suppressed inflammation induced by acute shear stress in endothelial cells: Implications for vein graft failure504Optical treatment of cardiac arrhythmias505Tachypacing-induced heart failure: a metabolomic investigation506Characterization of early left ventricle dysfunction in a relevant experimental model for human rheumatoid arthritis507Circadian rhythm in heart rate is due to an intrinsi. Cardiovascular Research, 2016, 111, S90	3.8	1
86	Blood smear, a key diagnostic tool in hematology: Lessons from two cases of acute hemolysis in previously undiagnosed G6PD deficiency. American Journal of Hematology, 2016, 91, 1165-1166.	4.1	2
87	Protease inhibitorsâ€based therapy induces acquired spherocyticâ€like anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients. Liver International, 2016, 36, 49-58.	3.9	11
88	Fentanyl Buccal Tablet: A New Breakthrough Pain Medication in Early Management of Severe Vasoâ€Occlusive Crisis in Sickle Cell Disease. Pain Practice, 2016, 16, 680-687.	1.9	12
89	A new molecular link between defective autophagy and erythroid abnormalities in chorea-acanthocytosis. Blood, 2016, 128, 2976-2987.	1.4	47
90	Pesticide toxicogenomics across scales: in vitro transcriptome predicts mechanisms and outcomes of exposure in vivo. Scientific Reports, 2016, 6, 38131.	3.3	20

#	Article	IF	Citations
91	Functional characterization of novel ABCB6 mutations and their clinical implications in familial pseudohyperkalemia. Haematologica, 2016, 101, 909-917.	3.5	30
92	Increased levels of ERFE-encoding FAM132B in patients with congenital dyserythropoietic anemia type II. Blood, 2016, 128, 1899-1902.	1.4	26
93	Neuronal Dysfunction in iPSC-Derived Medium Spiny Neurons from Chorea-Acanthocytosis Patients Is Reversed by Src Kinase Inhibition and F-Actin Stabilization. Journal of Neuroscience, 2016, 36, 12027-12043.	3.6	40
94	NCOA4 Deficiency Impairs Systemic Iron Homeostasis. Cell Reports, 2016, 14, 411-421.	6.4	167
95	Galectin-3 and Myocardial Fibrosis By Cardiac Magnetic Resonance in Thalassaemia Major. Blood, 2016, 128, 4832-4832.	1.4	2
96	Gender Differences in the Development of CMR Abnormalities and Cardiac Complications: A Multicentric Prospective Study in a Large Cohort of Thalassemia Major Patients. Blood, 2016, 128, 849-849.	1.4	1
97	A Selective ORAL GLYT1 Inhibitor, Improves Anemia and RED CELL Survival in a MOUSE MODEL of Beta-Thalassemia. Blood, 2016, 128, 1284-1284.	1.4	0
98	Hypoxia-reperfusion affects osteogenic lineage and promotes sickle cell bone disease. Blood, 2015, 126, 2320-2328.	1.4	45
99	Dietary Â-3 fatty acids protect against vasculopathy in a transgenic mouse model of sickle cell disease. Haematologica, 2015, 100, 870-880.	3.5	51
100	Abnormal Red Cell Structure and Function in Neuroacanthocytosis. PLoS ONE, 2015, 10, e0125580.	2.5	27
101	The Interplay Between Peroxiredoxin-2 and Nuclear Factor-Erythroid 2 Is Important in Limiting Oxidative Mediated Dysfunction in Î²-Thalassemic Erythropoiesis. Antioxidants and Redox Signaling, 2015, 23, 1284-1297.	5.4	45
102	Peroxiredoxin-2: A Novel Factor Involved in Iron Homeostasis. Blood, 2015, 126, 406-406.	1.4	1
103	Association Between Serum Ferritin and Liver Iron Concentration with Cardiac Iron in Pediatric Thalassemia Major Patients. Blood, 2015, 126, 956-956.	1.4	2
104	The Local Complement Activation on Vascular Bed of Patients with Systemic Sclerosis: A Hypothesis-Generating Study. PLoS ONE, 2015, 10, e0114856.	2.5	22
105	Resolvin D1 and Resolvin D2 Protect Against Hypoxia/Reoxygenation Induced Lung and Kidney Damage in a Sickle Cell Mouse Model of Acute Vaso-Occlusive Crisis. Blood, 2015, 126, 966-966.	1.4	0
106	Detection of Familial Pseudohyperkalemia Among Italian Blood Donors By Genetic Screening for the R276W Mutation in ABCB6. Blood, 2015, 126, 2132-2132.	1.4	0
107	Erfe-Encoding FAM132B in Congenital Dyserythropoietic Anemia Type II. Blood, 2015, 126, 535-535.	1.4	0
108	Resveratrol accelerates erythroid maturation by activation of FoxO3 and ameliorates anemia in beta-thalassemic mice. Haematologica, 2014, 99, 267-275.	3.5	89

#	Article	IF	Citations
109	Performance of a novel sieving matrix of poly(vinyl alcohol)/acrylamide copolymer in electrophoretic separations of high molecular weight proteins from red cell membrane. Electrophoresis, 2014, 35, 1081-1088.	2.4	1
110	Development of interactive algorithm for clinical management of acute events related to sickle cell disease in emergency department. Orphanet Journal of Rare Diseases, 2014, 9, 91.	2.7	14
111	Abnormal red cell features associated with hereditary neurodegenerative disorders. Current Opinion in Hematology, 2014, 21, 201-209.	2.5	25
112	The novel role of peroxiredoxin-2 in red cell membrane protein homeostasis and senescence. Free Radical Biology and Medicine, 2014, 76, 80-88.	2.9	35
113	A rare disorder in an orphan disease: Kikuchiâ€“Fujimoto disease in a youngâ€adult patient with sickle cell anemia. American Journal of Hematology, 2014, 89, 1151-1152.	4.1	1
114	Quantitative T2*MRI for Bone Marrow Iron Overload Assessment in Thalassemia Major and Intemedia Patients. Blood, 2014, 124, 4042-4042.	1.4	1
115	Pericardial Effusion Is a Marker of Increased Mortality in Thalassemia Major Patients. Blood, 2014, 124, 2689-2689.	1.4	0
116	Hemopexin Therapy Improves Cardiovascular Function by Preventing Heme-Induced Endothelial Toxicity in Mouse Models of Hemolytic Diseases. Circulation, 2013, 127, 1317-1329.	1.6	197
117	Pharmacological inhibition of calpainâ€1 prevents red cell dehydration and reduces Gardos channel activity in a mouse model of sickle cell disease. FASEB Journal, 2013, 27, 750-759.	0.5	28
118	Might Helicobacter pylori infection be associated with distortion on taste perception?. Medical Hypotheses, 2013, 81, 496-499.	1.5	9
119	Membrane association of peroxiredoxin-2 in red cells is mediated by the N-terminal cytoplasmic domain of band 3. Free Radical Biology and Medicine, 2013, 55, 27-35.	2.9	71
120	Missense mutations in the ABCB6 transporter cause dominant familialpseudohyperkalemia. American Journal of Hematology, 2013, 88, 66-72.	4.1	67
121	Quantitative analysis of murine terminal erythroid differentiation in vivo: novel method to study normal and disordered erythropoiesis. Blood, 2013, 121, e43-e49.	1.4	192
122	Immunoglobulinâ€resistant delayed hemolytic transfusion reaction treated with rituximab in an adult sickle cell patient. Transfusion, 2013, 53, 688-689.	1.6	14
123	An unusual case of sarcoidosis in an adult patient with sickle cell disease: Management with methotrexate and low dose of steroid. American Journal of Hematology, 2013, 88, 243-243.	4.1	3
124	Multiple clinical forms of dehydrated hereditary stomatocytosis arise from mutations in PIEZO1. Blood, 2013, 121, 3925-3935.	1.4	266
125	Oxidative Stress and<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:mi mathvariant="bold-italic">Î²</mml:mi></mml:mrow></mml:math>-Thalassemic Erythroid Cells behind the Molecular Defect. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-10.	4.0	57
126	Two-Photon Microscopy Imaging of thy1GFP-M Transgenic Mice: A Novel Animal Model to Investigate Brain Dendritic Cell Subsets In Vivo. PLoS ONE, 2013, 8, e56144.	2.5	23

#	Article	IF	Citations
127	Hypothyroidism and Cardiac Complications In Thalassemia Major Patients. Blood, 2013, 122, 2254-2254.	1.4	1
128	Left and Right Ventricular Wall Motion Abnormalities In Thalassemia Major Patients. Blood, 2013, 122, 2255-2255.	1.4	0
129	Myocardial and Hepatic Iron Overload and Cardiac Function In Sickle/Thalassemia Patients Of Italian Origin. Blood, 2013, 122, 2252-2252.	1.4	0
130	Calpain-1 knockout reveals broad effects on erythrocyte deformability and physiology. Biochemical Journal, 2012, 448, 141-152.	3.7	32
131	Computational Identification of Phospho-Tyrosine Sub-Networks Related to Acanthocyte Generation in Neuroacanthocytosis. PLoS ONE, 2012, 7, e31015.	2.5	19
132	Correlations Between Pancreatic Iron Burden and Heart Iron Overload and Function by MRI in a Large Cohort of Thalassemia Major Patients.. Blood, 2012, 120, 2123-2123.	1.4	1
133	Oxidative stress modulates heme synthesis and induces peroxiredoxin-2 as a novel cytoprotective response in Â-thalassemic erythropoiesis. Haematologica, 2011, 96, 1595-1604.	3.5	63
134	Erythrocyte membrane changes of chorea-acanthocytosis are the result of altered Lyn kinase activity. Blood, 2011, 118, 5652-5663.	1.4	73
135	Abnormal modulation of cell protective systems in response to ischemic/reperfusion injury is important in the development of mouse sickle cell hepatopathy. Haematologica, 2011, 96, 24-32.	3.5	26
136	Proteome analysis of biological fluids from autoimmuneâ€rheumatological disorders. Proteomics - Clinical Applications, 2011, 5, 78-89.	1.6	15
137	Thrombosis and Sickle Cell Disease. Seminars in Thrombosis and Hemostasis, 2011, 37, 226-236.	2.7	146
138	Onset of Cardiac Iron Loading in a Large and Homogeneous Cohort of Thalassemia Major Paediatric Patients. Blood, 2011, 118, 2157-2157.	1.4	0
139	Peroxiredoxin-2 expression is increased in Î²-thalassemic mouse red cells but is displaced from the membrane as a marker of oxidative stress. Free Radical Biology and Medicine, 2010, 49, 457-466.	2.9	55
140	Sickle cellâ€"related acute abdominal painful crisis complicating the clinical management of a cocaineâ€packer. American Journal of Hematology, 2010, 85, 792-792.	4.1	1
141	Current knowledge about the functional roles of phosphorylative changes of membrane proteins in normal and diseased red cells. Journal of Proteomics, 2010, 73, 445-455.	2.4	53
142	Deoxygenation affects tyrosine phosphoproteome of red cell membrane from patients with sickle cell disease. Blood Cells, Molecules, and Diseases, 2010, 44, 233-242.	1.4	30
143	Comparative Proteomic Analysis of Serum from Patients with Systemic Sclerosis and Sclerodermatous GVHD. Evidence of Defective Function of Factor H. PLoS ONE, 2010, 5, e12162.	2.5	19
144	Preliminary Evidence for Cell Membrane Amelioration in Children with Cystic Fibrosis by 5-MTHF and Vitamin B12 Supplementation: A Single Arm Trial. PLoS ONE, 2009, 4, e4782.	2.5	10

#	Article	IF	Citations
145	Cardiac troponin T during sickle cell crisis. International Journal of Cardiology, 2009, 136, 357-358.	1.7	11
146	A novel erythroid anion exchange variant (Gly796Arg) of hereditary stomatocytosis associated with dyserythropoiesis. Haematologica, 2009, 94, 1049-1059.	3.5	63
147	Oxidized and poorly glycosylated band 3 is selectively phosphorylated by Syk kinase to form large membrane clusters in normal and G6PD-deficient red blood cells. Biochemical Journal, 2009, 418, 359-367.	3.7	93
148	PATHOPHISIOLOGY OF SICKLE CELL DISEASE AND NEW DRUGS FOR THE TREATMENT. Mediterranean Journal of Hematology and Infectious Diseases, 2009, 1, e2009024.	1.3	32
149	PTPÏµ has a critical role in signaling transduction pathways and phosphoprotein network topology in red cells. Proteomics, 2008, 8, 4695-4708.	2.2	37
150	Heatâ€shock proteinâ€27, â€70 and peroxiredoxinâ€“II show molecular chaperone function in sickle red cells: Evidence from transgenic sickle cell mouse model. Proteomics - Clinical Applications, 2008, 2, 706-719.	1.6	32
151	Novel Inhibitors of the Gardos Channel for the Treatment of Sickle Cell Disease. Journal of Medicinal Chemistry, 2008, 51, 976-982.	6.4	56
152	Estimation of glomerular filtration rate by the modification of diet in renal disease (MDRD) equation in patients with sickle cell disease. Clinical Chemistry and Laboratory Medicine, 2008, 46, 1200-1.	2.3	2
153	Protective effects of phosphodiesteraseâ€4 (PDEâ€4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice. FASEB Journal, 2008, 22, 1849-1860.	0.5	30
154	Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. Journal of Clinical Investigation, 2008, 118, 1924-1933.	8.2	118
155	Phosphodiesterase-4 Inhibition Reduces Ischemic/Reperfusion Liver Injury in a Mouse Model for Sickle Cell Disease.. Blood, 2008, 112, 1444-1444.	1.4	1
156	BAND 3CEINGE (Gly796Arg) Mutation Causes Dehydrated Hereditary Stomatocytosis (DHS) with Dyserythropoietic Phenotype. Blood, 2008, 112, 2874-2874.	1.4	2
157	K-CL co-transport plays an important role in normal and Â thalassemic erythropoiesis. Haematologica, 2007, 92, 1319-1326.	3.5	18
158	Acute Hemolytic Anemia With Acanthocytosis Associated With High-Dose Misoprostol for Medical Abortion. Annals of Emergency Medicine, 2007, 50, 289-291.	0.6	10
159	Peroxiredoxin-2 (Prx-2) Shows a Dual Role as Antioxidant and Chaperone in Red Cells from a Î² Thalassemic Mouse Model.. Blood, 2007, 110, 1783-1783.	1.4	2
160	Heat-Shock Protein-70, -27 and Peroxiredoxin-2 Show Chaperone Function in Sickle Red Cells: Evidences from Transgenic Sickle Cell Mouse Model.. Blood, 2007, 110, 845-845.	1.4	0
161	Can 5-methyltetrahydrofolate modify the phospholipid fatty acid pattern in cystic fibrosis pediatric patients?. Journal of Cystic Fibrosis, 2006, 5, 197-199.	0.7	6
162	Effects of interferon plus ribavirin treatment on NF-ÎºB, TGF-Î²1, and metalloproteinase activity in chronic hepatitis C. Modern Pathology, 2006, 19, 1047-1054.	5.5	16

#	Article	IF	Citations
163	Regulation of Kâ€“Cl cotransport by protein phosphatase 1Î± in mouse erythrocytes. Pflugers Archiv European Journal of Physiology, 2006, 451, 760-768.	2.8	16
164	Protective effects ofS-nitrosoalbumin on lung injury induced by hypoxia-reoxygenation in mouse model of sickle cell disease. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2006, 291, L457-L465.	2.9	30
165	Effect of complete protein 4.1R deficiency on ion transport properties of murine erythrocytes. American Journal of Physiology - Cell Physiology, 2006, 291, C880-C886.	4.6	23
166	The Dual Endothelin Receptor Antagonist Bosentan Prevents the Acute Sickle Cell-Related Hypoxic Lung and Kidney Injury in Transgenic SAD Mice.. Blood, 2006, 108, 687-687.	1.4	4
167	Liver expression of hepcidin and other iron genes in two mouse models of beta-thalassemia. Haematologica, 2006, 91, 1336-42.	3.5	48
168	Evidence for a protective role of the Gardos channel against hemolysis in murine spherocytosis. Blood, 2005, 106, 1454-1459.	1.4	29
169	The N-terminal 11 amino acids of human erythrocyte band 3 are critical for aldolase binding and protein phosphorylation: implications for band 3 function. Blood, 2005, 106, 4359-4366.	1.4	76
170	Sickle cell disease and hyperreactive malarial splenomegaly (HMS) in young immigrants from Africa. Blood, 2005, 106, 4415-4417.	1.4	15
171	Protein phosphatase 1Î± is tyrosine-phosphorylated and inactivated by peroxynitrite in erythrocytes through the src family kinase fgr. Free Radical Biology and Medicine, 2005, 38, 1625-1636.	2.9	24
172	Acrylamide-agarose copolymers: Improved resolution of high molecular mass proteins in two-dimensional gel electrophoresis. Proteomics, 2005, 5, 2331-2339.	2.2	16
173	Ischemic Colitis Sustained by Sickle Cell Trait in Young Adult Patient. American Journal of Gastroenterology, 2005, 100, 2818-2821.	0.4	7
174	Pharmacological Inhibition of K-Cl Cotransport Alters In Vitro Maturation of Normal and Î²-Thalassemic Human Erythroid Progenitors.. Blood, 2005, 106, 3819-3819.	1.4	0
175	Selective intra-arterial terlipressin infusion stops acute lower gastrointestinal bleeding. European Journal of Gastroenterology and Hepatology, 2004, 16, 1059-1061.	1.6	6
176	Physiology and Pathophysiology of the Erythrocyte Gardos Channel in Hematological Diseases. Advances in Experimental Medicine and Biology, 2004, , 387-388.	1.6	0
177	New Insights into the Function of N-Terminal 11 Amino Acids of Band 3 from Structural and Functional Study of a Naturally Occuring Band 3 Variant.. Blood, 2004, 104, 577-577.	1.4	1
178	Protective Effects of No-Albumin and Albumin on Lung Injury Induced by Hypoxia/Reoxygenation in a Mouse Model of Sickle Cell Disease.. Blood, 2004, 104, 3580-3580.	1.4	0
179	Proteomics of Membrane from Human Sickle and Normal Fractioned Red Cells Identifies Different Expression of Stress-Response Proteins.. Blood, 2004, 104, 3568-3568.	1.4	0
180	Murine Spherocytosis: Evidence for a Functional Interaction between Protein 4.1 and Na/H Exchange and for a â€œProtectiveâ€•Role of the Gardos Channel Against Hemolysis.. Blood, 2004, 104, 578-578.	1.4	1

#	Article	IF	Citations
181	PDE-4 Inhibitor Rolipram Prevents Hypoxia Induced Pulmonary Hypertension in Transgenic Sickle Cell Sad Mice.. Blood, 2004, 104, 3577-3577.	1.4	0
182	Established and experimental treatments for sickle cell disease. Haematologica, 2004, 89, 348-56.	3.5	32
183	In vivo reduction of erythrocyte oxidant stress in a murine model of beta-thalassemia. Haematologica, 2004, 89, 1287-98.	3.5	47
184	A pilot study on the efficacy of ketorolac plus tramadol infusion combined with erythrocytapheresis in the management of acute severe vaso-occlusive crises and sickle cell pain. Haematologica, 2004, 89, 1389-91.	3.5	18
185	ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood, 2003, 101, 2412-2418.	1.4	180
186	Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation. Blood, 2003, 102, 1087-1096.	1.4	69
187	Erythrocyte-active agents and treatment of sickle cell disease. Seminars in Hematology, 2001, 38, 324-332.	3.4	16
188	K-Cl cotransport modulation by intracellular Mg in erythrocytes from mice bred for low and high Mg levels. American Journal of Physiology - Cell Physiology, 2001, 281, C1385-C1395.	4.6	28
189	Treatment with NS3623, a novel Cl-conductance blocker, ameliorates erythrocyte dehydration in transgenic SAD mice: a possible new therapeutic approach for sickle cell disease. Blood, 2001, 97, 1451-1457.	1.4	67
190	Erythrocyte[mdash]active agents and treatment of sickle cell disease. Seminars in Hematology, 2001, 38, 324-332.	3.4	9
191	Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage. Hepatology, 2000, 31, 997-1004.	7.3	426
192	Mouse K-Cl cotransporter KCC1: cloning, mapping, pathological expression, and functional regulation. American Journal of Physiology - Cell Physiology, 1999, 277, C899-C912.	4.6	87
193	Formation of Dense Erythrocytes in SAD Mice Exposed to Chronic Hypoxia: Evaluation of Different Therapeutic Regimens and of a Combination of Oral Clotrimazole and Magnesium Therapies. Blood, 1999, 94, 4307-4313.	1.4	50
194	Deferiprone therapy in homozygous human Î²-thalassemia removes erythrocyte membrane free iron and reduces KCl cotransport activity. Translational Research, 1999, 133, 64-69.	2.3	29
195	Formation of Dense Erythrocytes in SAD Mice Exposed to Chronic Hypoxia: Evaluation of Different Therapeutic Regimens and of a Combination of Oral Clotrimazole and Magnesium Therapies. Blood, 1999, 94, 4307-4313.	1.4	0
196	Dietary Magnesium Supplementation Ameliorates Anemia in a Mouse Model of Î²-Thalassemia. Blood, 1997, 90, 1283-1290.	1.4	49
197	Membrane cation and anion transport activities in erythrocytes of hereditary spherocytosis: Effects of different membrane protein defects. , 1997, 55, 121-128.		40
198	Dietary Magnesium Supplementation Ameliorates Anemia in a Mouse Model of Î²-Thalassemia. Blood, 1997, 90, 1283-1290.	1.4	0

#	Article	IF	Citations
199	Omega-3 polyunsaturated fatty acid supplements and ambulatory blood pressure monitoring parameters in patients with mild essential hypertension. Journal of Hypertension, 1995, 13, 1823???1826.	0.5	19
200	A linkage between hereditary hyperferritinaemia not related to iron overload and autosomal dominant congenital cataract. British Journal of Haematology, 1995, 90, 931-934.	2.5	100
201	Effect of cell age and phenylhydrazine on the cation transport properties of rabbit erythrocytes. Journal of Cellular Physiology, 1993, 154, 271-280.	4.1	50
202	Potassium Loss and Cellular Dehydration of Stored Erythrocytes following Incubation in Autologous Plasma: Role of the KCl Cotransport System. Vox Sanguinis, 1993, 65, 95-102.	1.5	18
203	Thalassemia Is Paradoxically Associated with a Reduced Risk of In-Hospital Complications and Mortality in COVID-19: Data from an International Registry. SSRN Electronic Journal, 0, , .	0.4	0